Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
11/9/2023 | Outperform → In-line | Evercore ISI | |
11/9/2023 | Buy → Neutral | H.C. Wainwright | |
11/9/2023 | $31.00 → $1.00 | Buy → Neutral | Mizuho |
7/20/2022 | $8.00 → $3.00 | Neutral → Sell | Citigroup |
7/13/2022 | $10.00 | Overweight → Neutral | JP Morgan |
7/13/2022 | $16.00 → $5.00 | Buy → Hold | Stifel |
5/10/2022 | $15.00 → $8.00 | Buy → Neutral | Citigroup |
1/3/2022 | $26.00 → $27.00 | Overweight | JP Morgan |
S-8 - Atara Biotherapeutics, Inc. (0001604464) (Filer)
8-K - Atara Biotherapeutics, Inc. (0001604464) (Filer)
8-K - Atara Biotherapeutics, Inc. (0001604464) (Filer)
Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the Company will release third quarter 2024 financial results after market close on Tuesday, Nov 12, 2024. About Atara Biotherapeutics, Inc. Atara is harnessing the natural power of the immune system to develop off-the-shelf cell therapies for difficult-to-treat cancers and autoimmune conditions that can be rapidly delivered to patients from inventory. With cutting-edge science and differentiated approach, Atara is the first company in the w
Pierre Fabre Laboratories to License Commercialization Rights to Tab-cel®, including Regulatory, Manufacturing and Development Activities, in the United States and All Remaining Markets Atara to Receive Additional Payments of up to USD 640 Million, Significant Double-digit Tiered Royalties as a Percentage of Net Sales, and Funding of Tab-cel Global Development Costs Tab-cel Global Partnership and Associated Strategic Restructuring Extends Atara Cash Runway into Q3 2025 ATA188 Phase 2 EMBOLD Study Primary Analysis and Communication on Track for Early November Atara to Host Conference Call and Webcast today at 6:00 a.m. PDT / 9:00 a.m. EDT Atara Biotherapeutics, Inc. (NASDAQ:ATRA),
Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the Company will release second quarter 2023 financial results after market close on Tuesday, August 8, 2023. About Atara Biotherapeutics, Inc. Atara is harnessing the natural power of the immune system to develop off-the-shelf cell therapies for difficult-to-treat cancers and autoimmune conditions, including multiple sclerosis, that can be rapidly delivered to patients within days. With cutting-edge science and differentiated approach, At
4 - Atara Biotherapeutics, Inc. (0001604464) (Issuer)
4 - Atara Biotherapeutics, Inc. (0001604464) (Issuer)
4 - Atara Biotherapeutics, Inc. (0001604464) (Issuer)
4 - Atara Biotherapeutics, Inc. (0001604464) (Issuer)
4 - Atara Biotherapeutics, Inc. (0001604464) (Issuer)
4 - Atara Biotherapeutics, Inc. (0001604464) (Issuer)
SC 13G/A - Atara Biotherapeutics, Inc. (0001604464) (Subject)
SC 13G/A - Atara Biotherapeutics, Inc. (0001604464) (Subject)
SC 13G/A - Atara Biotherapeutics, Inc. (0001604464) (Subject)
Eikon Therapeutics, Inc., a California-based biotechnology company that applies advanced engineering and high-performance computing to the identification of important new medicines, today announced the appointment of Roy D. Baynes, MB, BCh, MMed, PhD, as Executive Vice President and Chief Medical Officer, effective July 11, 2022. A gifted physician-scientist and leading oncologist, Dr. Baynes is among the most experienced – and most successful – clinical development leaders in the biopharmaceutical industry. Dr. Baynes will serve as a consultant to Eikon Therapeutics beginning April 1, 2022 before transitioning to his full-time role as Executive Vice President and Chief Medical Officer in J
Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the appointment of Ameet Mallik to the Board of Directors. Mr. Mallik is a biotechnology and pharmaceutical industry expert with a successful track record of bringing innovative oncology therapeutics, including CAR T cell therapy, to market in the U.S. and other countries. With more than 25 years of experience, Mr. Mallik adds relevant and directly applicable management and operational experience that will be instrumental as Atara progresses toward commercial laun
Evercore ISI downgraded Atara Biotherapeutics from Outperform to In-line
H.C. Wainwright downgraded Atara Biotherapeutics from Buy to Neutral
Mizuho downgraded Atara Biotherapeutics from Buy to Neutral and set a new price target of $1.00 from $31.00 previously
Atara received FDA Complete Response Letter (CRL) solely related to inspection findings at third-party manufacturer CRL did not identify deficiencies related to clinical efficacy or safety data in the Biologics License Application (BLA), and the FDA did not request any new clinical studies to support approval Atara remains committed to working with the FDA, Pierre Fabre Laboratories, and the third-party manufacturer to bring EBVALLO to patients in the U.S. Atara has engaged a well-known financial advisor to support exploration of all strategic options Atara remains focused on preserving future EBVALLO financial value for the benefit of all stockholders Atara has entered into a non
MIAMI, Dec. 04, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 77th Emerging Growth Conference on December 4 & 5, 2024. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter. Day 1December 4, 2024 9:00Virtual Lobby opens.Register for the Conference. If you already registered, go ba
MIAMI, Dec. 03, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 77th Emerging Growth Conference on December 4 & 5, 2024. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Day 1December 4, 2024 9:00Virtual Lobby opens.Register for the Conference. If you already registered, go bac